Literature DB >> 23996293

Inflammation and hypertension in rheumatoid arthritis.

Siriporn Manavathongchai1, Aihua Bian, Young Hee Rho, Annette Oeser, Joseph F Solus, Tebeb Gebretsadik, Ayumi Shintani, C Michael Stein.   

Abstract

OBJECTIVE: Hypertension (HTN), a common modifiable cardiovascular risk factor, is more common in patients with rheumatoid arthritis (RA), but the underlying mechanisms are unclear. We examined the hypothesis that mediators of inflammation and markers of cardiovascular risk are associated with HTN in RA.
METHODS: We compared measures of inflammation [serum C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), homocysteine, and leptin concentrations] and insulin resistance [homeostasis model assessment index (HOMA)] in RA patients with (n = 90) and without HTN (n = 79). HTN was defined as blood pressure ≥ 140/90 mm Hg or treatment with antihypertensive therapy. The independent association of markers of interest with HTN was examined using multivariable logistic regression.
RESULTS: Patients with HTN were significantly older and had longer disease duration than those without HTN (both p < 0.001). Concentrations of homocysteine [11.1 (8.5-13.5) μmol/l vs 9.3 (7.8-11.0) μmol/l] were significantly higher in patients with HTN (p < 0.001). After adjustment for age, sex, race, smoking, body mass index, and corticosteroid and nonsteroidal antiinflammatory drugs (NSAID) use, increased concentrations of homocysteine (OR 2.9, 95% CI: 1.5-5.5, p = 0.001), and leptin (OR 2.0, 95% CI: 1.0-3.8, p = 0.046) were significantly associated with HTN, but the 28-joint Disease Activity Score, IL-6, CRP, TNF-α, and HOMA index were not (all p > 0.05).
CONCLUSION: HTN in patients with RA is not associated with generalized systemic inflammation or insulin resistance, but is associated with increasing concentrations of homocysteine and leptin. The pathogenesis of HTN in RA may involve pathways more regularly associated with fat and vascular homeostasis.

Entities:  

Keywords:  BLOOD PRESSURE; HOMOCYSTEINE; HYPERTENSION; INFLAMMATION; LEPTIN; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2013        PMID: 23996293      PMCID: PMC3818311          DOI: 10.3899/jrheum.130394

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  42 in total

Review 1.  Leptin and cardiovascular disease: response to therapeutic interventions.

Authors:  Kwang Kon Koh; Sang Min Park; Michael J Quon
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

2.  Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Unhee Lim; Patricia A Cassano
Journal:  Am J Epidemiol       Date:  2002-12-15       Impact factor: 4.897

3.  Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension.

Authors:  Santina Cottone; Giuseppe Mulè; Emilio Nardi; Anna Vadalà; Marco Guarneri; Chiara Briolotta; Rosalia Arsena; Alessandro Palermo; Raffaella Riccobene; Giovanni Cerasola
Journal:  Am J Hypertens       Date:  2006-03       Impact factor: 2.689

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis.

Authors:  Ratchaya Lertnawapan; Aihua Bian; Young Hee Rho; Vivian K Kawai; Paolo Raggi; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  J Rheumatol       Date:  2011-08-15       Impact factor: 4.666

6.  Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women.

Authors:  Howard D Sesso; Lu Wang; Julie E Buring; Paul M Ridker; J Michael Gaziano
Journal:  Hypertension       Date:  2006-12-11       Impact factor: 10.190

7.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

8.  Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.

Authors:  V F Panoulas; K M J Douglas; A Stavropoulos-Kalinoglou; G S Metsios; P Nightingale; M D Kita; M S Elisaf; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2008-01       Impact factor: 7.580

9.  Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.

Authors:  Cecilia P Chung; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; Ingrid Avalos; Tuulikki Sokka; Paolo Raggi; Theodore Pincus; C Michael Stein
Journal:  Arthritis Rheum       Date:  2008-07

Review 10.  Hypertension in rheumatoid arthritis.

Authors:  V F Panoulas; G S Metsios; A V Pace; H John; G J Treharne; M J Banks; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2008-05-08       Impact factor: 7.580

View more
  16 in total

Review 1.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 2.  Role of Inflammatory Diseases in Hypertension.

Authors:  E Bartoloni; A Alunno; V Valentini; F Luccioli; E Valentini; G La Paglia; O Bistoni; Roberto Gerli
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-09

3.  Longterm blood pressure variability in patients with rheumatoid arthritis and its effect on cardiovascular events and all-cause mortality in RA: a population-based comparative cohort study.

Authors:  Elena Myasoedova; Cynthia S Crowson; Abigail B Green; Eric L Matteson; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2014-07-01       Impact factor: 4.666

Review 4.  Emerging role of leptin in rheumatoid arthritis.

Authors:  G Tian; J-N Liang; Z-Y Wang; D Zhou
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

5.  Association between urinary sodium and potassium excretion and blood pressure and inflammation in patients with rheumatoid arthritis.

Authors:  Daniel Carranza-Leon; Rany Octaria; Michelle J Ormseth; Annette Oeser; Joseph F Solus; Yahua Zhang; Chimalum R Okafor; Jens Titze; C Michael Stein; Cecilia P Chung
Journal:  Clin Rheumatol       Date:  2017-12-14       Impact factor: 2.980

6.  Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants.

Authors:  Stefan Siebert; Donald M Lyall; Daniel F Mackay; Duncan Porter; Iain B McInnes; Naveed Sattar; Jill P Pell
Journal:  RMD Open       Date:  2016-06-14

7.  Prevalence of Asymptomatic Arterial Hypertension and Its Correlation with Inflammatory Activity in Early Rheumatoid Arthritis.

Authors:  Ismet H Bajraktari; Sylejman Rexhepi; Idriz Berisha; Ali Lahu; Avni Kryeziu; Bastri Durmishi; Halit Bajraktari; Elton Bahtiri
Journal:  Open Access Maced J Med Sci       Date:  2017-08-10

8.  Association between inflammation and systolic blood pressure in RA compared to patients without RA.

Authors:  Zhi Yu; Seoyoung C Kim; Kathleen Vanni; Jie Huang; Rishi Desai; Shawn N Murphy; Daniel H Solomon; Katherine P Liao
Journal:  Arthritis Res Ther       Date:  2018-06-01       Impact factor: 5.156

9.  Risk of developing depressive disorders following rheumatoid arthritis: a nationwide population-based study.

Authors:  Shu-Li Wang; Cheng-Ho Chang; Li-Yu Hu; Shih-Jen Tsai; Albert C Yang; Zi-Hong You
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  Leptin regulates disc cartilage endplate degeneration and ossification through activation of the MAPK-ERK signalling pathway in vivo and in vitro.

Authors:  Ying-Chao Han; Bin Ma; Song Guo; Mingjie Yang; Li-Jun Li; Shan-Jin Wang; Jun Tan
Journal:  J Cell Mol Med       Date:  2018-01-26       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.